ZNGA, YUM, URGN Stocks Upgraded Today

Cowen raised its price target on Yum shares after they hit an all-time peak on Friday

May 30, 2017 at 9:18 AM
facebook X logo linkedin

Analysts are weighing in on internet game developer Zynga Inc (NASDAQ:ZNGA), Taco Bell parent Yum! Brands, Inc. (NYSE:YUM), and healthcare stock Urogen Pharma Ltd (NASDAQ:URGN). Here's a quick roundup of today's bullish brokerage notes on shares of ZNGA, YUM, and URGN.

ZNGA Stock Upgraded at Piper Jaffray

Ahead of Thursday's appearance at the Cowen Technology, Media & Telecom Conference, Zynga saw its rating raised to "overweight" from "neutral," and its price target upped to $4 from $3 at Piper Jaffray. The brokerage firm said that despite increased competition for game stocks, ZNGA's strong management team -- which includes former members of Electronic Arts -- and its focus on cost containment "improve its risk profile."

After closing Friday at $3.49, ZNGA stock is up 2.6% in electronic trading. This would just be more of the same for Zynga shares, which are up 45% from their February low of $2.40 -- and hit a three-year high of $3.63 last Thursday. Most analysts remain on the sidelines, though, with a tepid "hold" recommendation, while the average 12-month price target stands at $3.47.

YUM Stock Price Target Raised After Record High

Several strong bounces off its 200-day moving average earlier this year helped YUM stock soar to a record high $72.52 on Friday, with the shares eventually settling at $71.03 -- up 13.8% on the year. This may be what prompted Cowen and Company to boost their price target on the security to $85 from $80. Regardless, there's plenty of room for more analysts to upwardly revise their ratings, which could draw more buyers to Yum stock's table. More than half of the 16 covering brokerages maintain a "hold" rating, while the consensus annual price target of $74.32 represents a slim 3.1% premium to YUM's current perch.

Brokerage Firms Issue "Buy" Ratings on URGN Stock 

URGN stock received the equivalent of a "buy" initiation from no fewer than four brokerage firms, with Cowen and Company waxing optimistic over the drugmaker's MitoGel and VesiGel cancer treatments. Urogen Pharma went public earlier this month, and since its May 4 open at $13.28, the stock has surged more than 39%, based on Friday's close at $18.48.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI